News

Mark J. Roschewski, MD, discusses standard of care options for the treatment of follicular lymphoma.

The combination of dendritic cell-based immunotherapy in the second-line of treatment for patients with ovarian cancer proves beneficial.

The novel PARP inhibitor RP12146 has been administered to the first patient in a phase 1/1b clinical trial of patients with advanced solid tumors.

Catherine Callaghan Coombs, MD, discusses the mechanism of action of pirtobrutinib in chronic lymphocytic leukemia and small lymphocytic leukemia.

Filip Janku, MD, PhD, discussed the efficacy of the PI3K inhibitor copanlisib in solid tumors in an interview with Targeted Oncology.

A recently published study has shown no difference in survival outcomes for patients under 50 with colorectal cancer, despite greater treatment intensity and physical fitness.

The PDUFA date for Cilta-Cel has been moved in order to evaluate new data and is now set for early 2022.

Here is a look back FDA happenings from October 2021.

Sarah P. Psutka, MD, discusses the key findings of a retrospective study of the efficacy of Immune checkpoint inhibitor plus tyrosine kinase inhibitor as any-line treatment for patients with renal cell carcinoma.

he CINtec PLUS Cytology duel-stain biomarker technology was found to be more sensitive than Pap in detecting cervical precancer in women with HPV.

The biologics license application for toripalimab will undergo a speedy review by the FDA for consideration as a frontline treatment option for patients with advanced recurrent or metastatic nasopharyngeal carcinoma in combination with gemcitabine and cisplatin, and as a single-agent for the second-line or above treatment of recurrent or metastatic disease after platinum-containing chemotherapy.

Emergency Use Authorization granted for young children may address cases of severe disease, which is more common in pediatric patients with cancer compared with children without cancer.

The FDA is considering an application parsaclisib as treatment of patients with relapsed or refractory follicular lymphoma, marginal zone lymphoma, and mantle cell lymphoma, and granted priority review for 2 of the 3 indications.

The Pinal Cancer & Surgery Center in Casa Grande, Arizona has joined the American Oncology Network.

Sergio A. Giralt, MD, discusses the key goals of the SIERRA trial which evaluated the safety and efficacy of I apamistamab versus conventional chemotherapy for the treatment of older patients with relapsed/refractory acute myeloid leukemia.

Joseph M. Curry, MD, discussed the efficacy of durvalumab in combination with metformin for the treatment of squamous cell carcinoma of the head and neck during an interview with Targeted Oncology.

The trial is evaluating the safety and efficacy of taletrectinib in ROS1 NSCLC. Taletrectinib is a novel TKI.

Extended follow-up of patients in COSMIC-311 showed continued survival benefit and tumor reduction with cabozantinib versus placebo in patients with radioactive iodine-refractory differentiated thyroid cancer.

Two approvals for asciminib were issued by the FDA for the treatment of CML with a Ph+ mutation.

In a phase 1 dose-escalation study, an investigational BTK degrader showed clinically meaningful results in patients with chronic lymphocytic leukemia and elicited a response.

Retrospective data suggest that perinephric fat invasion, sarcomatoid or rhabdoid component, and necrosis are independent prognostic indicators of recurrence-free survival in renal cell carcinoma.

Jesús García-Foncillas, MD, PhD, discussed the comparison of larotrectinib versus entrectinib for the treatment of NTRK fusion-positive tumors in an interview with Targeted OncologyTM.

While some studies have found that obesity provides a survival advantage in certain cancers, sarcopenia obesity was found to be associated with worse survival outcomes in patients with endometrial cancer.

A gene therapy development initiative from the FDA, National Institute of Health and 15 other organizations may move CRISPR closer to use in patients with rare cancers.

Efficacy observed with the combination of devimistat and modified FOLFIRINOX in patients with metastatic pancreatic cancer has lead to a negative result in the phase 3 AVENGER 500 clinical trial.

NBTXR3, which is activated by radiotherapy, was found to be safe and tolerable in frail patients with head and neck squamous cell carcinoma. The agent can be used on its own or in combination with other immunotherapy agents.

Jason Westin, MD, discusses the future of diffuse large B-cell lymphoma treatment.

Florida Cancer Specialists & Research Institute, in collaboration with AdventHealth Heart of Florida and Central Florida Cancer Institute, has received a 3-year accreditation from the National Accreditation Program for Breast Centers.

Lead investigator Arndt Vogel, MD, discussed the use of immunotherapy in earlier-stage HCC and findings from the IMMUTACE in an interview with Targeted Oncology.

After discovering the potential of a prophylactic breast cancer vaccine, Cleveland Clinic will be the site of a phase 1 clinical trial to test its safety.